Jeff Cislini has sold RVMD and made no open-market buys since Jun 2023

Jeff Cislini is a Senior Vice President, General Counsel and Corporate Secretary at Revolution Medicines, Inc., a clinical-stage precision oncology company focused on targeted therapies for RAS-addicted cancers.( He has served as Senior Vice President, General Counsel and Secretary since September 2022, after initially joining the company in 2020 as Vice President, Deputy General Counsel, during which time he acted as the company’s senior legal advisor.( Recent securities filings and insider trading reports identify him as an officer and General Counsel of Revolution Medicines in connection with multiple pre‑planned stock transactions under Rule 10b5‑1 trading plans.(

Cislini brings more than 20 years of legal experience advising on corporate governance, securities law, contracts, compliance, intellectual property, privacy, and employment law.( Before his promotion to the senior management team at Revolution Medicines, he built a broad in‑house and advisory background supporting high‑growth companies on complex corporate and regulatory matters.( Public profiles describe him as holding a J.D. (Juris Doctor) degree, reflecting formal legal training, and as a seasoned corporate counsel contributing to the company’s governance and strategic transactions as a key member of its executive leadership.(

Written by Perplexity from public sources.